Abramson JS et al. Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) with salvage chemotherapy followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL): Primary analysis of the randomized, phase 3 Transform study. ASH 2022;Abstract 655.
Abramson J et al. Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) for second-line (2L) treatment of patients (pt) with refractory/early relapsed (R/R) large B-cell lymphoma (LBCL). ASH 2022;Abstract 2031.
Alderuccio JP et al. Metabolic tumor volume predicts outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with loncastuximab tesirine in the lotis-2 trial. ASH 2022;Abstract 2960.
Bartlett N et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal Phase II Study. ASH 2022;Abstract 610.
Batlevi CL et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of Symphony-1. ASH 2022;Abstract 954.
Dreyling M et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. ASH 2022;Abstract 1.
Dreyling M et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the Elara trial. ASH 2022;Abstract 608.
Herrera AF et al. Exploratory analysis of factors influencing efficacy and safety of camidanlumab tesirine: Data from the open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL). ASH 2022;Abstract 1594.
Herrera AF et al. Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): Results from the POLARIX study. ASH 2022;Abstract 542.
Hou J-Z et al. Interim results of the phase 1 study of Tnb-486, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) B-NHL. ASH 2022;Abstract 612.
Hutchings M et al. Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment. ASH 2022;Abstract 441.
Leonard JP et al. Five-year results and overall survival update from the phase 3 randomized study augment: Lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2022;Abstract 230.
Locke FL et al. Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in ZUMA-7. ASH 2022;Abstract 259.
Lunning MA et al. Outcomes of axicabtagene ciloleucel in comparison with chemoimmunotherapy (CIT) in an elderly population for treatment of relapsed or refractory (r/r) large b-cell lymphoma (LBCL) after two or more lines of prior therapy. ASH 2022;Abstract 765.
Mei M et al. Nivolumab plus ICE as first salvage therapy in high-risk relapsed/refractory Hodgkin lymphoma. ASH 2022;Abstract 318.
Munoz J et al. Assessment of durable responses after brexucabtagene autoleucel (KTE-X19) in the ZUMA-2 study in relapsed/refractory mantle cell lymphoma (R/R MCL). ASH 2022;Abstract 4199.
Neelapu S et al. 3-year follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2022;Abstract 4660.
Olszewski AJ et al. Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. ASH 2022;Abstract 738.
Phillips TJ et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. ASH 2022;Abstract 74.
Ruan J et al. Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-naïve mantle cell lymphoma. ASH 2022;Abstract 73.
Thieblemont C et al. Iberdomide (CC-220) monotherapy or in combination with an anti-CD20 monoclonal antibody as effective therapy in patients with relapsed/refractory lymphoma: Early results from a phase 1/2 study. ASH 2022;Abstract 233.